Business
NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2022, as filed with the Securities and Exchange Commission, is available through its website (https://www.neurosense-tx.com), and provided a business update.\nShareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).\n\"During the fourth quarter, we continued to make progress in advancing our lead combination drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS) in the Phase 2b PARADIGM trial. As over 50% of the patients have been enrolled, we expect to release topline results in the second half of 2023,\" stated NeuroSense's CEO, Alon Ben-Noon. \"We obtained positive results in a biomarker study in Alzheimer's disease and plan to commence a Phase 2 trial for this indication during the first half of this year. The complexity of neurological diseases, including ALS and Alzheimer's, may be more effectively treated with combination therapies, which operate through multiple mechanisms of action. We are targeting multiple value-driving milestones in 2023.\"\nBusiness Update\nPhase 2b ALS Trial: Enrollment ongoing in Italy & Israel, and approved to commence in CanadaNeuroSense achieved several milestones during Q4 in the clinical development of PrimeC, its lead drug candidate currently being evaluated in PARADIGM, a double-blind, randomized, placebo-controlled, multi-national Phase 2b clinical trial. Over 50% of the patients have been enrolled. At the beginning of 2023, the first patient was enrolled in Italy. Health Canada approved the trial to commence enrollment in Canada, with patients dosing expected to commence in the beginning of Q2 2023.NeuroSense withdrew its protocol from its U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) in order to align its clinical strategy with the FDA for its planned pivotal Phase 3 trial and New Drug Application (NDA) submission based on the results of the PARADIGM study and results of additional studies we intend to conduct in th...